UCB SA (UCBJY)
| Market Cap | 34.66B |
| Revenue (ttm) | 5.84B |
| Net Income (ttm) | 257.15M |
| Shares Out | n/a |
| EPS (ttm) | 1.31 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | 0.46 (0.46%) |
| Ex-Dividend Date | Apr 26, 2024 |
| Volume | 100 |
| Open | 89.13 |
| Previous Close | 86.95 |
| Day's Range | 88.90 - 89.79 |
| 52-Week Range | 36.70 - 99.40 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Feb 27, 2025 |
About UCB SA
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company’s primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson’s disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epi... [Read more]
Financial Performance
In 2023, UCB SA's revenue was 5.18 billion, a decrease of -4.87% compared to the previous year's 5.45 billion. Earnings were 343.00 million, a decrease of -17.94%.
Financial numbers in EUR Financial StatementsNews
Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside
On Tuesday, UCB SA (OTC: UCBJY) (OTC: UCBJF) and Biogen Inc. (NASDAQ: BIIB) presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP) for systemic lupus ery...
FDA Approves UCB's Psoriasis Drug For Expanded Use In Painful Inflammatory Skin Disease
On Wednesday, the FDA approved UCB SA’s (OTC: UCBJY) (OTC: UCBJF) Bimzelx (bimekizumab-bkzx) for adults with moderate to severe hidradenitis suppurativa (HS). Bimekizumab-bkzx is the first and only ...
UCB gets FDA approval for Bimzelx for hidradenitis suppurativa
Biogen, UCB release phase 3 data on lupus candidate dapirolizumab
United Community Banks: Too Rich For My Blood
United Community Banks' balance sheet shows mixed results in deposits and debt. Read more to see why I think UCB stock is a sell.
Bimzelx Powers UCB To New Heights: Deep Dive Into The Company's Growth Strategy
UCB SA has a promising drug, Bimzelx, despite temporary EBITDA decline and potential regulatory hurdles ahead. Learn more about UCBJF stock here.
UCB Announces Late-Breaking Two-Year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024
Clinically meaningful improvements observed with BIMZELX over one year of treatment were maintained up to two years (Week 96) At Week 96, over eight in 10 patients treated with BIMZELX achieved HiSCR5...
UCB Presents New 4-year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Plaque Psoriasis at EADV 2024
Responder analyses demonstrated that approximately nine out of 10 patients treated with BIMZELX who achieved PASI90 at Year 1, and over seven out of 10 patients who achieved complete skin clearance (P...
Biogen and Belgian partner UCB announce positive data from late-stage trial of lupus treatment
Biogen Inc.’s stock rose 2% early Tuesday, after the company and Belgian partner UCB announced positive results in a late-stage trial
Biogen, UCB mark late-stage trial win for autoimmune disease therapy
Biogen (BIIB) and UCB (UCBJY) announce a Phase 3 trial win for an experimental therapy targeting Systemic Lupus Erythematosus (SLE). Read more here.
UCB gets expanded FDA approval for psoriasis drug Bimzelx
UCB (UCBJY) (UCBJF) said it has received FDA approval for its drug Bimzelx for the treatment of active psoriatic arthritis, ankylosing spondylitis, and nr-axSpA. Read more here.
Week In Review: UCB Sells China Drug Portfolio For $680 Million To CBC
Belgium-Based Pharma Firm UCB To Offload China Neurology, Allergy Business For $680M To Asset Management Companies
European biopharmaceutical company UCB SA (OTC: UCBJF) (OTC: UCBJY) announced a $680 million strategic divestment deal in China. The transaction involves the sale, divestment, and license of UCB’s m...
Abu Dhabi fund Mubadala invests in UCB Pharma's China carve-out
The sovereign fund partners with Asia's healthcare investor to acquire 100% in the carve-out
Belgium's UCB to sell China neurology and allergy business for $680 mln
UCB, a Belgian biopharmaceutical firm, said on Monday that it will sell its Chinese neurology and allergy business to asset management group CBC and Abu Dhabhi's Mubadala for $680 million.
Mubadala co-invests in UCB's mature business in China to reinforce its long-term commitment to the Asian market
The transaction remains subject to certain closing conditions, including required anti-trust clearance(s) and other customary conditions, and is expected to close in Q4 2024
United Community Banks: Preferred Share Downgrade On Low Yield
United Community Banks has seen changes in business due to rising interest rates, but net interest income remains strong. Learn more about UCB stock here.
UCB SA (UCBJF) Q2 2024 Earnings Call Transcript
UCB SA (OTCPK:UCBJF) Q2 2024 Earnings Conference Call July 25, 2024 8:00 AM ET Company Participants Antje Witte - Head, IR Jean-Christophe Tellier - CEO Sandrine Dufour - CFO Emmanuel Caeymaex - CCO I...
UCB SA (UCBJF) Full Year 2023 Earnings Call Transcript
UCB SA (OTCPK:UCBJF) Full Year 2023 Earnings Conference Call February 28, 2024 8:00 AM ET Company Participants Antje Witte – Investor Relations Jean-Christophe Tellier – Chief Executive Officer Emmanu...